Associations of aldosterone synthase gene polymorphism and atrial fibrillation affected by coronary heart disease in elderly and senile patients

Given the significant increase in the frequency of atrial fibrillation (AF) in elderly and senile patients with confirmed coronary heart disease (CHD), the study of the relationship between the polymorphisms responsible for the functioning of the renin-angiotensinaldosterone system and the presence of this disease becomes relevant. Purpose of the study. To study the genetic polymorphism of the CYP11B2 gene in elderly patients with ischemic heart disease, as well as to identify the role of aldosterone synthetase in the development of AF in this category of patients. Materials and methods. The study included 140 patients of both sexes (54,3% – men), over the age of 60 years, with confirmed coronary artery disease and any form of AF (the last episode no later than 12 months from the date of inclusion in the study). 84 patients agreed to participate in the study of aldosterone synthase polymorphisms. The control group consisted of 34 patients who had no diagnosed non-infectious diseases at the time of the survey. Both groups were comparable in age and sex characteristics. Results. Comparative evaluation of the distribution of genotypes and alleles – C344/T of the aldosterone synthase gene among patients with AF+CHD and relatively healthy individuals revealed that in the first group, most patients had the CYP11B2 T/T genotype in 38,1% of cases, the incidence was higher, than in patients of the comparison group – 14,7% (OR = 3.44, CI 1.07-11.07, p = 0.038). The frequency of detection of genotypes of CYP11B2 С/T and CYP11B2 С/С did not significantly differ in the compared groups. In the group with AF+CHD, the T allele was significantly more common (53,6% vs. 35,3%; p<0,05), while the frequency of occurrence of allele C was significantly higher in the group of relatively healthy individuals (64,3% vs. 47,1%; p<0,05). Conclusion. AF in elderly and senile patients with CHD is associated with the presence of CYP11B2 T/T genotype (OR = 3,44, DI 1,07–11,07, p = 0,038) and is not associated with myocardial echocardiographic parameters, including the size of left atrium.

aldosterone synthase (CYP11B2), atrial fibrillation, advanced age, endothelial dysfunction, RAAS

1. Abdel Hamid M., Bakhoum S.W., Sharaf Y., Sabry D., El-Gengehe A.T., Abdel-Latif A. Circulating Endothelial Cells and Endothelial Function Predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction. J Interv Cardiol. 2016 Feb;29(1):89-98. doi: 10.1111/joic.12269.

2. Mordi I., Mordi N., Delles C., Tzemos N. Endothelial dysfunction in human essential hypertension. J Hypertens. 2016 Aug;34(8):1464- 72. doi: 10.1097/HJH.0000000000000965.

3. Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;(57):590–600. doi: 10.1016/j. jacc.2010.07.053.

4. Yan G., Wang Y. Association of CYP11B2 gene polymorphism with ischemic stroke in the north Chinese Han population. Neurol India. 2012;(60):504–509. doi: 10.4103/0028- 3886.103196.

5. Bzoma B., Debska-Slizień A., Dudziak M., Raczyńska K., Slizień W., Brylowska A., Rutkowski B. Genetic predisposition to systemic complications of arterial hypertension in maintenance haemodialysis patients. Pol Merkur Lekarski. 2008 Sep;25(147):209-16. Available at: https://www.ncbi.nlm.nih.gov/pub med/?term=Genetic+predisposition+to+systemi c+complications+of+arterial+hypertension+in+ maintenance+haemodialysis+patients.

6. Lu W.H., Bayike M., Liu J.W., Wang S., Xie X., Yang Y.C., Liu F., Li N., Liu Z.Q., He P.Y., Muhuyati. Association between aldosterone synthase (CYP11B2) -344C/T polymorphism and atrial fibrillation among Han and Kazak residents of the Xinjiang region. Int J Clin Exp Med. 2015 Apr 15;8(4):5513-9. Available at: https://www. ncbi.nlm.nih.gov/pubmed/?term=Association+b etween+aldosterone+synthase+(CYP11B2)+- 344C%2FT+polymorphism+and+atrial+fibrillati on+among+Han+and+Kazak+residents+of+the+ Xinjiang+region.

7. Orenes-Piñero E., Hernández-Romero D., Romero-Aniorte A.I., Martínez M., GarcíaHonrubia A., Caballero L., Garrigos-Gómez N., Andreu-Cayuelas J.M., González J., Feliu E., Climent V., Nicolás-Ruiz F., De La Morena G., Valdés M., Lip G.Y., Marín F. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. QJM. 2014;107(8):613-21. doi: 10.1093/qjmed/hcu046.

8. Электронный ресурс: Хельсинкская декларация Всемирной медицинской ассоциации: рекомендации для врачей по проведению биомедицинских исследований на людях. Режим доступа: https://www.mediasphera.ru/ journals/mjmp/2000/4/r4-00-20.htm. Electronic Resource: Helsinki Declaration of the World Medical Association. (In Russ) Available at: https://www.mediasphera.ru/journals/mjmp/2000/4/r4-00-20.htm. Date of latest renewal: August 24, 2018.

9. Rutherford R.B., Baker J.D., Ernst C., Johnston K.W., Porter J.M., Ahn S., Jones D.N. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517-538. doi: 10.1016/ s0741-5214(97)70045-4.

10. Dewland T.A., Olgin J.E., Vittinghoff E., Marcus G.M. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation. 2013;128(23):2470-7. doi: 10.1161/ CIRCULATIONAHA.113.002449.

11. Keenan N.L., Rosendorf K.A. Centers for Disease Control and Prevention. Prevalence of hypertension and controlled hypertension – United States, 2005–2008. MMWR Suppl. 2011;60(1):94-7. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/su6001a21.htm.

12. Lubitz S.A., Lunetta K.L., Lin H., Arking D.E., Trompet S., Li G., Krijthe B.P., Chasman D.I., Barnard J., Kleber M.E., Dörr M., Ozaki K., Smith A.V., Müller-Nurasyid M., Walter S., Agarwal S.K., Bis J.C., Brody J.A., Chen L.Y., Everett B.M., Ford I., Franco O.H., Harris T.B., Hofman A., Kääb S., Mahida S., Kathiresan S., Kubo M., Launer L.J., MacFarlane P.W., Magnani J.W., McKnight B., McManus D.D., Peters A., Psaty B.M., Rose L.M., Rotter J.I., Silbernagel G., Smith J.D., Sotoodehnia N., Stott D.J., Taylor K.D., Tomaschitz A., Tsunoda T., Uitterlinden A.G., Van Wagoner D.R., Völker U., Völzke H., Murabito J.M., Sinner M.F., Gudnason V., Felix S.B., März W., Chung M., Albert C.M., Stricker B.H., Tanaka T., Heckbert S.R., Jukema J.W., Alonso A., Benjamin E.J., Ellinor P.T. Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol. 2014;63(12):1200–10. doi: 10.1016/j. jacc.2013.12.015

13. Chalazan B., Mol D., Sridhar A., Alzahrani Z., Darbar S.D., Ornelas-Loredo A., Farooqui A., Argos M., Daviglus M.L., Konda S., Rehman J., Darbar D. Genetic modulation of atrial fibrillation risk in a Hispanic/Latino cohort. PLoS One. 2018 Apr 6;13(4):e0194480. doi: 10.1371/journal.pone.0194480.

14. Савинкова Е.А., Заварин В.В., Мазур Е.С. Генетический полиморфизм в патогенезе артериальной гипертензии и гипертрофии левого желудочка. Верхневолжский медицинский журнал. 2012;10(2):16-21. Режим доступа: https://elibrary.ru/item.asp?id=17839377. Savinkova E.A., Zavarin V.V., Mazur E.S. Genetic polymorphismin patogenesis of hypertension and left ventricular hypertrofy. Verkhnevolzhskiy meditsinskiy zhurnal = Upper Volga Medical Journal. 2012;10(2):16-21. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17839377.